Delirium Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Delirium Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

The 7 major delirium markets reached a value of US$ 187.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 283.0 Million by 2034, exhibiting a growth rate (CAGR) of 3.83% during 2024-2034.

The delirium market has been comprehensively analyzed in IMARC's new report titled "Delirium Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Delirium is a sudden and severe impairment of mental function that causes confused thinking and reduced awareness of surroundings. Some of the common symptoms of the disease are the inability to focus or concentrate, difficulty processing information, impaired memory, and hallucinations or delusions. Patients may also experience fluctuations in their level of consciousness, with periods of hyperactivity followed by lethargy or lethargy followed by hyperactivity. Various other indications of delirium include agitation, anxiety, restlessness, sleep disturbances, altered appetite, etc. The diagnosis of delirium is primarily based on a clinical assessment of the patient's symptoms and cognitive function, as well as an examination of their medical history and medications. The healthcare professional may review the patient's medical history and mental status by testing attention, awareness, and thinking. A physical test and neurological examination that include evaluating the vision, coordination, balance, and reflexes are required for further diagnosis. Additionally, several blood, urine, and brain imaging tests are also performed to rule out any underlying issues among patients.

The rising prevalence of neurological disorders, owing to several associated triggering factors, including genetic defects, congenital abnormalities, nerve injuries, etc., is primarily driving the delirium market. In addition to this, the widespread adoption of medications like antipsychotics and benzodiazepines for managing the symptoms of delirium, such as agitation, hallucinations, delusions, etc., is further acting as a significant growth-inducing factor. Moreover, the escalating usage of cognitive testing, including the mini-mental state examination (MMSE), as part of the delirium diagnosis to assess baseline cognitive function and detect changes associated with the ailment is also propelling the market growth. Apart from this, several key players are making extensive investments in understanding the underlying mechanisms of delirium, such as changes in brain function and the role of inflammation, for identifying new approaches to prevention and treatment of the disease. This, in turn, is further creating a positive outlook for the market. Additionally, the emerging popularity of standardized assessment tools, including the confusion assessment method (CAM) and the delirium observation screening scale (DOSS), which enable non-psychiatrically trained clinicians to identify and diagnose the ailment accurately and quickly, is expected to drive the delirium market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the delirium market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for delirium and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the delirium market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the delirium market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the delirium market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current delirium marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the delirium market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the delirium market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the delirium market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (​2018-2034​) of delirium across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of delirium by age across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of delirium by gender across the seven major markets?
What is the number of prevalent cases (​2018-2034​) of delirium by type across the seven major markets?
How many patients are diagnosed (​2018-2034​) with delirium across the seven major markets?
What is the size of the delirium patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of delirium?
What will be the growth rate of patients across the seven major markets?

Delirium: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for delirium drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the delirium market?
What are the key regulatory events related to the delirium market?
What is the structure of clinical trial landscape by status related to the delirium market?
What is the structure of clinical trial landscape by phase related to the delirium market?
What is the structure of clinical trial landscape by route of administration related to the delirium market?